BiomX Inc.
8.09%
889,928
1739174
May 25, 2026
May 28, 2026, 06:13 PM
Reporting Persons (6)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Deerfield Management Company, L.P. | Partnership | 8.09% | 889,928 | 0 | 889,928 |
| James E. Flynn | Individual | 8.09% | 889,928 | 0 | 889,928 |
| Deerfield Private Design Fund V, L.P. | Partnership | 4.08% | 444,703 | 0 | 444,703 |
| Deerfield Mgmt V, L.P. | Partnership | 4.08% | 444,703 | 0 | 444,703 |
| Deerfield Healthcare Innovations Fund II, L.P. | Partnership | 4.08% | 444,703 | 0 | 444,703 |
| Deerfield Mgmt HIF II, L.P. | Partnership | 4.08% | 444,703 | 0 | 444,703 |
Disclosure Items (4)
Common Stock, par value $0.0001 per share
BiomX Inc.
850 NEW BURTON ROAD, DOVER, DE, 19904
Item 3 of the Schedule 13D is hereby amended and supplemented by adding the following: On May 27, 2026, each Fund exercised its Amended and Restated Warrant (in full) for 66,242 shares of Common Stock (the "Pre-Funded Warrant Exercise Shares"). Each Fund elected to pay the aggregate exercise price for its Pre-Funded Warrant Exercise Shares of $125.86, in cash, utilizing such Fund's cash on hand. In addition, on May 28, 2026, each Fund converted 47,957 shares of Series X Preferred Stock held by such Fund into 252,397 shares of Common Stock.
Items 5(a), (b) and (c) of the Schedule 13D are hereby amended and restated in their entirety as follows: (1) Deerfield Mgmt V, L.P. Number of shares: 444,703 (comprised of shares of Common Stock and shares of Common Stock underlying warrants, in each case, held by Deerfield Private Design Fund V, L.P.) Percentage of Shares: 4.08%* (2) Deerfield Private Design Fund V, L.P. Number of shares: 444,703 (comprised of shares of Common Stock and shares of Common Stock underlying warrants,) Percentage of Shares: 4.08%* (3) Deerfield Mgmt HIF II, L.P., L.P. Number of shares: 444,703 (comprised of shares of Common Stock and shares of Common Stock underlying warrants, in each case, held by Deerfield Healthcare Innovations Fund II, L.P.) Percentage of Shares: 4.08%* (4) Deerfield Healthcare Innovations Fund II, L.P. Number of shares: 444,703 (comprised of shares of Common Stock and shares of Common Stock underlying warrants) Percentage of Shares: 4.08%* (5) Deerfield Management Number of shares: 889,928 (comprised of (i) shares of Common Stock and shares of Common Stock underlying warrants, in each case, held by Deerfield Private Design Fund V, L.P. and Deerfield Healthcare Innovations Fund II, L.P. and (ii) shares of Common Stock issuable upon exercise of options held by Jonathan Leff for the benefit, and at the direction, of Deerfield Management) Percentage of Shares: 8.09%* (6) Flynn Number of shares: 889,928 (comprised of (i) shares of Common Stock and shares of Common Stock underlying warrants, in each case, held by Deerfield Private Design Fund V, L.P. and Deerfield Healthcare Innovations Fund II, L.P. and (ii) shares of Common Stock issuable upon exercise of options held by Jonathan Leff for the benefit, and at the direction, of Deerfield Management) Percentage of Shares: 8.09%* *Throughout this report, the percentage of outstanding shares of Common Stock beneficially owned by the Reporting Persons reflects 10,783,794 shares of Common Stock outstanding, based on (i) 10,146,516 shares of Common Stock outstanding as of May 20, 2026, as set forth in the Company's Quarterly Report on Form 10-Q, filed by the Company with the Securities and Exchange Commission (the "SEC") on May 20, 2026, and (ii) an additional 637,278 shares of Common Stock issued to the Funds upon exercise of the Amended and Restated Warrants and the conversion of shares of Series X Preferred Stock, as disclosed in Item 3.
(1) Deerfield Mgmt V, L.P. Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 444,703 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 444,703 (2) Deerfield Private Design Fund V, L.P. Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 444,703 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 444,703 (3) Deerfield Mgmt HIF II, L.P. Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 444,703 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 444,703 (4) Deerfield Healthcare Innovations Fund II, L.P. Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 444,703 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 444,703 (5) Deerfield Management Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 889,928 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 889,928 (6) Flynn Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 889,928 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 889,928 Flynn is the sole manager of the general partner of each of Deerfield Mgmt V and Deerfield Mgmt HIF II and Deerfield Management. Deerfield Mgmt V is the general partner of Deerfield Private Design Fund V, L.P.; Deerfield Mgmt HIF II is the general partner of Deerfield Healthcare Innovations Fund II, L.P.; and Deerfield Management is the investment manager of each Fund. Each Fund purchases, holds and sells securities and other investment products. Schedule A hereto sets forth information regarding persons referred in Instruction C to Schedule 13D.
Transactions in the Common Stock effected by the Reporting Persons since the filing of Amendment No. 5 to the Schedule 13D are set forth on Exhibit 99.10 to this Amendment or disclosed in Item 3 to this Amendment. All transactions reflected in Exhibit 99.10 to this Amendment were effected in open market transactions on the Nasdaq Global Market in the ordinary course of the applicable Reporting Person's business.
Item 7 of the Schedule 13D is hereby amended and supplemented by adding the following: Exhibit Index Exhibit 99.10 - Transactions in Securities